Zobrazeno 1 - 10
of 17
pro vyhledávání: '"John F R Robertson"'
Autor:
Ola H Negm, Mohamed R Hamed, Robert E Schoen, Richard L Whelan, Robert J Steele, John Scholefield, Elizabeth M Dilnot, H M C Shantha Kumara, John F R Robertson, Herbert F Sewell
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0156971 (2016)
Colorectal cancer (CRC) is the second most common malignancy in the western world. Early detection and diagnosis of all cancer types is vital to improved prognosis by enabling early treatment when tumours should be both resectable and curable. Sera f
Externí odkaz:
https://doaj.org/article/c8dee0905a3840ccbf39eb0bb574f986
Autor:
Catrin H Middleton, William Irving, John F R Robertson, Andrea Murray, Celine B Parsy-Kowalska, Isabel K Macdonald, Jane McElveen, Jared Allen, Graham F Healey, Brian J Thomson, Stephen J Ryder, Stefan Holdenrieder, Caroline J Chapman
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e103867 (2014)
BACKGROUND: Individuals with liver disease, and especially those with Hepatitis B or C, are at an increased risk of developing hepatocellular carcinoma (HCC) which is the third most common cause of cancer-related death worldwide. Inadequate screening
Externí odkaz:
https://doaj.org/article/4dca7442513c4446a6c64c6c158599b5
Autor:
Isabel K Macdonald, Jared Allen, Andrea Murray, Celine B Parsy-Kowalska, Graham F Healey, Caroline J Chapman, Herbert F Sewell, John F R Robertson
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e40759 (2012)
An assay employing a panel of tumor-associated antigens has been validated and is available commercially (EarlyCDT®-Lung) to aid the early detection of lung cancer by measurement of serum autoantibodies. The high throughput (HTP) strategy described
Externí odkaz:
https://doaj.org/article/30b6bdc9b68c4fcf9e3b714380df206a
Autor:
Isabel K Macdonald, Andrea Murray, Graham F Healey, Celine B Parsy-Kowalska, Jared Allen, Jane McElveen, Chris Robertson, Herbert F Sewell, Caroline J Chapman, John F R Robertson
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e51002 (2012)
BackgroundThe National Lung Screening Trial showed that CT screening for lung cancer led to a 20% reduction in mortality. However, CT screening has a number of disadvantages including low specificity. A validated autoantibody assay is available comme
Externí odkaz:
https://doaj.org/article/8438960788f54e9abee9c438965f1446
Autor:
Judith M. Bliss, Holly Tovey, Abigail Evans, Chris Holcombe, Kieran Horgan, Elizabeth Mallon, Raghavan Vidya, Anthony Skene, Andrew Dodson, Margaret Hills, Simone Detre, Lila Zabaglo, Jane Banerji, Lucy Kilburn, James P. Morden, John F. R. Robertson, Ian Smith, Mitch Dowsett, the POETIC Trialists
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Purpose Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week) is associated with clinical benefit fro
Externí odkaz:
https://doaj.org/article/46abcee1eee44a268049c2e73c029025
Publikováno v:
BMJ (Clinical research ed.). 373
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::02fd0dd4d430a82e327164ba17fb68c9
https://pubmed.ncbi.nlm.nih.gov/33722904
https://pubmed.ncbi.nlm.nih.gov/33722904
Autor:
John F R, Robertson, Abigail, Evans, Stephan, Henschen, Cliona C, Kirwan, Ali, Jahan, Laura M, Kenny, J Michael, Dixon, Peter, Schmid, Ashutosh, Kothari, Omar, Mohamed, Peter A, Fasching, Kwok-Leung, Cheung, Rachel, Wuerstlein, Danielle, Carroll, Teresa, Klinowska, Justin P O, Lindemann, Alexander, MacDonald, Richard, Mather, Rhiannon, Maudsley, Michele, Moschetta, Myria, Nikolaou, Martine P, Roudier, Tinnu, Sarvotham, Gaia, Schiavon, Diansong, Zhou, Li, Zhou, Nadia, Harbeck
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(16)
Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ERPatients were randomized 1:1 to receive AZD9496 250 mg twice daily from day 1 for 5-14 days, or fulvestrant 500 mg on day 1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1fc3aab84509bacc8fc54984bed818df
https://pubmed.ncbi.nlm.nih.gov/32234755
https://pubmed.ncbi.nlm.nih.gov/32234755
Autor:
John F R, Robertson, Robert E, Coleman, Kwok-Leung, Cheung, Abigail, Evans, Chris, Holcombe, Anthony, Skene, Daniel, Rea, Samreen, Ahmed, Ali, Jahan, Kieran, Horgan, Petra, Rauchhaus, Roberta, Littleford, S Y Amy, Cheung, Marie, Cullberg, Elza C, de Bruin, Loumpiana, Koulai, Justin P O, Lindemann, Martin, Pass, Paul, Rugman, Gaia, Schiavon, Rahul, Deb, Pauline, Finlay, Andrew, Foxley, Julia M W, Gee
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(7)
The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate key biomarkers of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3a399b61dedcefcdc40a05da71cadb65
https://pubmed.ncbi.nlm.nih.gov/31836609
https://pubmed.ncbi.nlm.nih.gov/31836609
Autor:
Ben Young, Kavita Vedhara, Denise Kendrick, Roberta Littleford, John F. R. Robertson, Frank M. Sullivan, Stuart Schembri, Roshan das Nair, in collaboration with the ECLS study team
Publikováno v:
BMC Public Health
BMC Public Health, Vol 18, Iss 1, Pp 1-13 (2018)
BMC Public Health, Vol 18, Iss 1, Pp 1-13 (2018)
Funding: Dundee Cancer Centre Development Fund. Oncimmune Ltd. and Chief Scientist Office, Scottish Government funded the ECLS Study. Background: The promotion of smoking cessation within lung cancer screening could lead to benefits for smoking-relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::922ef8eb08ae99feb145c04021e01bd8
https://pubmed.ncbi.nlm.nih.gov/30453929
https://pubmed.ncbi.nlm.nih.gov/30453929
Autor:
Amit, Agrawal, John F R, Robertson, Kwok L, Cheung, Eleanor, Gutteridge, Ian O, Ellis, Robert I, Nicholson, Julia M W, Gee
Publikováno v:
International Journal of Cancer
We report the first study of the biological effect of fulvestrant on ER positive clinical breast cancer using sequential biopsies through to progression. Thirty‐two locally/systemically advanced breast cancers treated with first‐line fulvestrant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e4fdaf6cf577f1ae26f633ca754e633
https://pubmed.ncbi.nlm.nih.gov/26178788
https://pubmed.ncbi.nlm.nih.gov/26178788